NASDAQ:SBBP Strongbridge Biopharma - SBBP Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Strongbridge Biopharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$1.95▼$2.0650-Day Range$1.89▼$2.2952-Week Range$1.85▼$4.26Volume684,684 shsAverage Volume866,464 shsMarket Capitalization$135.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Strongbridge Biopharma (NASDAQ:SBBP) StockStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Read More Receive SBBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SBBP Stock News HeadlinesJanuary 11, 2023 | marketwatch.comDay One Biopharma Shares Rise 13% After Positive Topline Results for TovorafenibSeptember 22, 2022 | markets.businessinsider.comAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and PatientsMarch 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. September 23, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.August 31, 2021 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With XerisAugust 5, 2021 | finance.yahoo.comStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateAugust 2, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy StatementJuly 29, 2021 | finance.yahoo.comStrongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021March 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. July 29, 2021 | finance.yahoo.comStrongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in IssueJuly 28, 2021 | nasdaq.comStrongbridge Biopharma's (NASDAQ:SBBP) Stock Price Has Reduced 48% In The Past Three YearsJuly 27, 2021 | finance.yahoo.comStrongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseJuly 26, 2021 | msn.comBRIEF-Strongbridge Biopharma Plc, Unit, Avenue Venture Opportunities Fund Enter Amendment To A Term Loan AgreementJuly 15, 2021 | nasdaq.comStrongbridge Biopharma plc Ordinary Shares (SBBP)July 13, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & NerveJune 29, 2021 | markets.businessinsider.comTudor Capital Europe LLP : Form 8.3 - Strongbridge Biopharma PlcJune 3, 2021 | finance.yahoo.comStrongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s SyndromeMay 29, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Strongbridge Biopharma plc - SBBPMay 29, 2021 | businesswire.comSTRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...May 28, 2021 | finance.yahoo.comSTRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBPMay 25, 2021 | businesswire.comStrongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are ...May 24, 2021 | benzinga.comStrongbridge Biopharma Merger Investigation:...May 24, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Investigates Strongbridge Biopharma plcMay 24, 2021 | finance.yahoo.comStrongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SBBPMay 24, 2021 | finance.yahoo.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Strongbridge Biopharma plc (Nasdaq - SBBP)May 24, 2021 | markets.businessinsider.comMid-Afternoon Market Update: Dow Jumps 250 Points; Scopus BioPharma Shares Spike HigherMay 24, 2021 | msn.comWhy Strongbridge Biopharma's Stock Is Trading Higher TodaySee More Headlines Receive SBBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SBBP Company Calendar Last Earnings8/05/2021Today3/27/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SBBP CUSIPN/A CIK1634432 Webwww.strongbridgebio.com Phone(610) 254-9200FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,080,000.00 Net Margins-115.67% Pretax MarginN/A Return on Equity-66.82% Return on Assets-36.21% Debt Debt-to-Equity Ratio0.38 Current Ratio3.00 Quick Ratio2.95 Sales & Book Value Annual Sales$30.73 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book2.04Miscellaneous Outstanding Shares67,829,000Free FloatN/AMarket Cap$135.66 million OptionableOptionable Beta1.58 Key ExecutivesJohn H. JohnsonChief Executive Officer & DirectorRichard S. KollenderPresident & Chief Financial OfficerFredric CohenChief Medical OfficerBrian ConnerChief Compliance OfficerPeter J. ValentinssonSenior Vice President-Global Technical OperationsKey CompetitorsGracell BiotechnologiesNASDAQ:GRCLAraviveNASDAQ:ARAVCorMedixNASDAQ:CRMDOlema PharmaceuticalsNASDAQ:OLMAESSA PharmaNASDAQ:EPIXView All Competitors SBBP Stock - Frequently Asked Questions How were Strongbridge Biopharma's earnings last quarter? Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings data on Thursday, August, 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analysts' expectations of $8.83 million. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 66.82% and a negative net margin of 115.67%. What other stocks do shareholders of Strongbridge Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB). What is Strongbridge Biopharma's stock symbol? Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP." What is Strongbridge Biopharma's stock price today? One share of SBBP stock can currently be purchased for approximately $2.00. How much money does Strongbridge Biopharma make? Strongbridge Biopharma (NASDAQ:SBBP) has a market capitalization of $135.66 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45,080,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. How can I contact Strongbridge Biopharma? Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The official website for the company is www.strongbridgebio.com. The biotechnology company can be reached via phone at (610) 254-9200 or via email at investors@strongbridgebio.com. This page (NASDAQ:SBBP) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.